LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 07/13/22

(TheNewswire) Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. Kelowna, British Columbia – TheNewswire - July 13, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Na...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its DehydraTECH licensee Boldt Runners Corporation, owners of the Cannadips brand, has expanded manufacturing agreements to include Europe, Japan and South Africa. “We are d...

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 7, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the signing of two agreements with Atlanta-based BevNology LLC. According to the update, the first manufacturing operating agreement expands production capabilities for Lexaria’s...

(TheNewswire) Expands DehydraTECH™ B2B manufacturing capabilities to support Lexaria’s growing corporate customer base Lexaria to also receive royalty revenue from DehydraTECH product sales through BevNology’s commercial license rig...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the u...

DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand markets Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexar...

KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has successfully filed a pre-Investigational New Drug ("IND") meeting request letter with the U...

(TheNewswire) Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity Lexaria to receive royalty revenue from DehydraTECH product sales Kelowna, British Columbia – TheNewswire - June 2, ...

KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting (the "Meeting"). On May 31, 2022 at 1:00 p.m. (Pacific Time), the Compa...